Meeting Highlights: American Heart Association Scientific Sessions 2001

Publisher Website
Google Scholar
Abstract
Major clinical subgroups, in men and women, and in all age subgroups. Furthermore, there was benefit regardless of baseline LDL or total cholesterol and benefit with further LDL lowering even in patients already at target LDL levels of 100 mg/dL. Simvastatin was well tolerated. Myopathy was reported in 0.1% of participants; liver function test abnor- malities (3 upper limits of normal) were reported in 0.8% of the simvastatin group and 0.6% of the placebo group. Summary: In patients at increased risk for cardiovascular disease who might not otherwise be deemed to be candidates for HMG-CoA reductase inhibitor therapy, 40 mg per day of simvastatin was associated with substantial reductions in cardiovascular events. These benefits were present regardless of initial LDL (even 100 mg/dL) and total cholesterol level, in men and women of all ages, and in patients with diabetes without preexisting coronary heart disease.

This publication has 0 references indexed in Scilit: